Deltec Asset Management LLC Sells 100 Shares of Johnson & Johnson (NYSE:JNJ)

Deltec Asset Management LLC lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,914 shares of the company’s stock after selling 100 shares during the quarter. Deltec Asset Management LLC’s holdings in Johnson & Johnson were worth $619,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also modified their holdings of the business. Sandy Cove Advisors LLC boosted its stake in shares of Johnson & Johnson by 4.4% during the 1st quarter. Sandy Cove Advisors LLC now owns 5,597 shares of the company’s stock worth $885,000 after acquiring an additional 238 shares during the last quarter. Trilogy Capital Inc. lifted its stake in shares of Johnson & Johnson by 91.5% during the 1st quarter. Trilogy Capital Inc. now owns 4,392 shares of the company’s stock valued at $695,000 after buying an additional 2,099 shares in the last quarter. Red Door Wealth Management LLC lifted its stake in shares of Johnson & Johnson by 2.0% during the 1st quarter. Red Door Wealth Management LLC now owns 47,322 shares of the company’s stock valued at $7,486,000 after buying an additional 921 shares in the last quarter. Cornerstone Wealth Group LLC lifted its stake in shares of Johnson & Johnson by 63.3% during the 1st quarter. Cornerstone Wealth Group LLC now owns 52,737 shares of the company’s stock valued at $8,343,000 after buying an additional 20,446 shares in the last quarter. Finally, FIDELIS iM LLC purchased a new position in shares of Johnson & Johnson during the 1st quarter valued at $202,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of analyst reports. HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their target price for the company from $169.00 to $170.00 in a research note on Thursday, April 18th. Royal Bank of Canada restated an “outperform” rating and set a $175.00 target price on shares of Johnson & Johnson in a research note on Monday, June 17th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Sunday. Morgan Stanley reduced their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 17th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Monday. Eight research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $174.07.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $146.42 on Tuesday. The company’s 50-day moving average price is $148.14 and its 200-day moving average price is $154.05. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $175.97. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. The company has a market cap of $352.39 billion, a PE ratio of 9.13, a price-to-earnings-growth ratio of 2.43 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm had revenue of $21.38 billion for the quarter, compared to the consensus estimate of $21.39 billion. During the same period in the previous year, the firm posted $2.68 EPS. The business’s quarterly revenue was up 2.3% on a year-over-year basis. On average, equities research analysts forecast that Johnson & Johnson will post 10.62 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.39%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date of this dividend was Monday, May 20th. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.